Journal of Comprehensive Pediatrics

Published by: Kowsar

Anthracycline-Induced Cardiothoxicity in Children Cancer Patients: An Imaging Study by Two-Dimensional Global Longitudinal Strain Using Automated Function Imaging Technique

Mohammad Reza Mirzaaghayan 1 , Leili Koochakzade 2 , Aalie Safari 2 , Mohammad Taghi Majnoon 1 , Ali-Asghar Zeinaloo 1 , Chehreh Mahdavi 1 , Azin Ghamari 3 , Ehsan Aghaei Moghadam 1 , * , Armen Kocharian 1 , Farzad Kompani 2 and Maryam Nikoufar 1
Authors Information
1 Division of Pediatric Cardiology, Children’s Medical Center Tehran University of Medical Sciences, Tehran, Iran
2 Division of Pediatric Oncology, Children’s Medical Center, Tehran University of Medical Sciences, Tehran, Iran
3 Tehran University of Medical Sciences, Tehran, Iran
Article information
  • Journal of Comprehensive Pediatrics: August 2018, 9 (3); e59701
  • Published Online: July 22, 2018
  • Article Type: Research Article
  • Received: August 7, 2017
  • Revised: April 8, 2018
  • Accepted: April 16, 2018
  • DOI: 10.5812/compreped.59701

To Cite: Mirzaaghayan M R, Koochakzade L, Safari A, Majnoon M T, Zeinaloo A, et al. Anthracycline-Induced Cardiothoxicity in Children Cancer Patients: An Imaging Study by Two-Dimensional Global Longitudinal Strain Using Automated Function Imaging Technique, J Compr Ped. 2018 ;9(3):e59701. doi: 10.5812/compreped.59701.

Abstract
Copyright © 2018, Journal of Comprehensive Pediatrics. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited
1. Background
2. Methods
3. Results
4. Discussion
References
  • 1. National Cancer Insitute NIoH , DHHS , Bethesda MD. Cancer Trends Progress Report. 2011/2012.
  • 2. Middleman E, Luce J, Frei E. Clinical trials with adriamycin. Cancer. 1971;28(4):844-50. doi: 10.1002/1097-0142(1971)28:4<844::aid-cncr2820280407>3.0.co;2-9.
  • 3. Curigliano G, Cardinale D, Suter T, Plataniotis G, de Azambuja E, Sandri MT, et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol. 2012;23 Suppl 7:vii155-66. doi: 10.1093/annonc/mds293. [PubMed: 22997448].
  • 4. Giantris A, Abdurrahman L, Hinkle A, Asselin B, Lipshultz SE. Anthracycline-induced cardiotoxicity in children and young adults. Crit Rev Oncol Hematol. 1998;27(1):53-68. doi: 10.1016/S1040-8428(97)10007-5. [PubMed: 9548017].
  • 5. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. 2009 Focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines developed in collaboration with the International Society for Heart and Lung Transplantation. J Am Coll Cardiol. 2009;53(15):e1-e90. doi: 10.1016/j.jacc.2008.11.013. [PubMed: 19358937].
  • 6. Romond EH, Jeong JH, Rastogi P, Swain SM, Geyer CE Jr, Ewer MS, et al. Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2012;30(31):3792-9. doi: 10.1200/JCO.2011.40.0010. [PubMed: 22987084]. [PubMed Central: PMC3478574].
  • 7. Cramer L, Hildebrandt B, Kung T, Wichmann K, Springer J, Doehner W, et al. Cardiovascular function and predictors of exercise capacity in patients with colorectal cancer. J Am Coll Cardiol. 2014;64(13):1310-9. doi: 10.1016/j.jacc.2014.07.948. [PubMed: 25257631].
  • 8. Ganame J, Claus P, Uyttebroeck A, Renard M, D'Hooge J, Bijnens B, et al. Myocardial dysfunction late after low-dose anthracycline treatment in asymptomatic pediatric patients. J Am Soc Echocardiogr. 2007;20(12):1351-8. doi: 10.1016/j.echo.2007.04.007. [PubMed: 17604960].
  • 9. Cardinale D, Colombo A, Lamantia G, Colombo N, Civelli M, De Giacomi G, et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol. 2010;55(3):213-20. doi: 10.1016/j.jacc.2009.03.095. [PubMed: 20117401].
  • 10. Yu CM, Sanderson JE, Marwick TH, Oh JK. Tissue Doppler imaging a new prognosticator for cardiovascular diseases. J Am Coll Cardiol. 2007;49(19):1903-14. doi: 10.1016/j.jacc.2007.01.078. [PubMed: 17498573].
  • 11. Sanz MA, Martin G, Rayon C, Esteve J, Gonzalez M, Diaz-Mediavilla J, et al. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA group. Blood. 1999;94(9):3015-21. [PubMed: 10556184].
  • 12. Tallman MS, Nabhan C, Feusner JH, Rowe JM. Acute promyelocytic leukemia: evolving therapeutic strategies. Blood. 2002;99(3):759-67. [PubMed: 11806975].
  • 13. Barrett-Lee PJ, Dixon JM, Farrell C, Jones A, Leonard R, Murray N, et al. Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk. Ann Oncol. 2009;20(5):816-27. doi: 10.1093/annonc/mdn728. [PubMed: 19153118].
  • 14. Smith LA, Cornelius VR, Plummer CJ, Levitt G, Verrill M, Canney P, et al. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer. 2010;10:337. doi: 10.1186/1471-2407-10-337. [PubMed: 20587042]. [PubMed Central: PMC2907344].
  • 15. Von Hoff DD, Layard MW, Basa P, Davis HL Jr, Von Hoff AL, Rozencweig M, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979;91(5):710-7. doi: 10.7326/0003-4819-91-5-710. [PubMed: 496103].
  • 16. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003;97(11):2869-79. doi: 10.1002/cncr.11407. [PubMed: 12767102].
  • 17. Limat S, Demesmay K, Voillat L, Bernard Y, Deconinck E, Brion A, et al. Early cardiotoxicity of the CHOP regimen in aggressive non-Hodgkin's lymphoma. Ann Oncol. 2003;14(2):277-81. doi: 10.1093/annonc/mdg070. [PubMed: 12562656].
  • 18. Sawyer DB, Peng X, Chen B, Pentassuglia L, Lim CC. Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection? Prog Cardiovasc Dis. 2010;53(2):105-13. doi: 10.1016/j.pcad.2010.06.007. [PubMed: 20728697]. [PubMed Central: PMC2933091].
  • 19. Felker GM, Thompson RE, Hare JM, Hruban RH, Clemetson DE, Howard DL, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med. 2000;342(15):1077-84. doi: 10.1056/NEJM200004133421502. [PubMed: 10760308].
  • 20. Rodvold KA, Rushing DA, Tewksbury DA. Doxorubicin clearance in the obese. J Clin Oncol. 1988;6(8):1321-7. doi: 10.1200/JCO.1988.6.8.1321. [PubMed: 3411343].
  • 21. Sawaya H, Sebag IA, Plana JC, Januzzi JL, Ky B, Tan TC, et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging. 2012;5(5):596-603. doi: 10.1161/CIRCIMAGING.112.973321. [PubMed: 22744937]. [PubMed Central: PMC3703313].
  • 22. Harake D, Franco VI, Henkel JM, Miller TL, Lipshultz SE. Cardiotoxicity in childhood cancer survivors: strategies for prevention and management. Future Cardiol. 2012;8(4):647-70. doi: 10.2217/fca.12.44. [PubMed: 22871201]. [PubMed Central: PMC3870660].
  • 23. Hoffmann R, von Bardeleben S, ten Cate F, Borges AC, Kasprzak J, Firschke C, et al. Assessment of systolic left ventricular function: a multi-centre comparison of cineventriculography, cardiac magnetic resonance imaging, unenhanced and contrast-enhanced echocardiography. Eur Heart J. 2005;26(6):607-16. doi: 10.1093/eurheartj/ehi083. [PubMed: 15618026].
  • 24. Florescu M, Magda LS, Enescu OA, Jinga D, Vinereanu D. Early detection of epirubicin-induced cardiotoxicity in patients with breast cancer. J Am Soc Echocardiogr. 2014;27(1):83-92. doi: 10.1016/j.echo.2013.10.008. [PubMed: 24268372].
  • 25. Ali MT, Yucel E, Bouras S, Wang L, Fei HW, Halpern EF, et al. Myocardial strain is associated with adverse clinical cardiac events in patients treated with anthracyclines. J Am Soc Echocardiogr. 2016;29(6):522-7 e3. doi: 10.1016/j.echo.2016.02.018. [PubMed: 27068546].
  • 26. Pignatelli RH, Ghazi P, Reddy SC, Thompson P, Cui Q, Castro J, et al. Abnormal myocardial strain indices in children receiving anthracycline chemotherapy. Pediatr Cardiol. 2015;36(8):1610-6. doi: 10.1007/s00246-015-1203-8. [PubMed: 26049414].
  • 27. Corapcioglu F, Sarper N, Berk F, Sahin T, Zengin E, Demir H. Evaluation of anthracycline-induced early left ventricular dysfunction in children with cancer: a comparative study with echocardiography and multigated radionuclide angiography. Pediatr Hematol Oncol. 2006;23(1):71-80. doi: 10.1080/08880010500313603. [PubMed: 16326416].
  • 28. Ishii M, Tsutsumi T, Himeno W, Eto G, Furui J, Hashino K, et al. Sequential evaluation of left ventricular myocardial performance in children after anthracycline therapy. Am J Cardiol. 2000;86(11):1279-81. A9. [PubMed: 11090811].
  • 29. Agha H, Shalaby L, Attia W, Abdelmohsen G, Aziz OA, Rahman MY. Early ventricular dysfunction after anthracycline chemotherapy in children. Pediatr Cardiol. 2016;37(3):537-44. doi: 10.1007/s00246-015-1311-5. [PubMed: 26667956].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments